Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
Oct 17, 2024 · When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I hadn’t heard of it. I immediately began a…. Many factors helped columnist Sam Kirton know when it was time to stop working so he could better attend to his health issues with IPF.
New prototype therapy may repair IPF lung scarring by …
Apr 26, 2024 · Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports.
BMS-986278 declared breakthrough therapy for progressive PF
Oct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF.
Idiopathic Pulmonary Fibrosis – Pulmonary Fibrosis News
Oct 28, 2021 · Read about idiopathic pulmonary fibrosis (IPF) — its risk factors, symptoms, and current ways of treating this interstitial lung disease.
Zelasudil wins FDA orphan drug status as IPF treatment candidate
Aug 25, 2023 · Zelasudil, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s now being tested in clinical trials, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA).
Oral BMS-986278 slows lung decline in progressive PF, Phase 2...
Sep 25, 2023 · The experimental oral therapy BMS-986278, taken at 60 mg twice daily for 26 weeks, resulted in a 69% reduction in the rate of lung function decline in adults with progressive pulmonary fibrosis taking part in a Phase 2 trial.
Study: ENV-101 improves IPF lung function, reverses fibrosis
Jun 7, 2024 · Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial.
Pulmonary Fibrosis News Forums
This is a space for the community to discuss healthcare resources and information. Supplements and Non-traditional Management of PF Diagnosis Information and General Questions Upcoming Medical Appointments: Q&As Coronavirus (COVID-19) …
Saracatinib as Effective, or Superior to Ofev, Esbriet in IPF...
Aug 30, 2022 · AstraZeneca’s experimental oral therapy saracatinib — originally developed to treat certain cancers — was found to be at least as effective, and even superior to the approved therapies Ofev (nintedanib) and Esbriet (pirfenidone) in treating idiopathic pulmonary fibrosis (IPF) in several preclinical models of the respiratory disease.
A new twist in my journey: Familial idiopathic pulmonary fibrosis
Sep 10, 2024 · Pulmonary fibrosis, however, can be hereditary. Perhaps someone in our genealogy passed on the disease, though sadly, it may have been undiagnosed. A person can be diagnosed with familial pulmonary fibrosis and the causes could still be idiopathic, or unknown.